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ABSTRACT
In this comparative biomarker study, we analysed 1768 
serial sputum samples from 178 patients at 4 sites in 
Southeast Africa. We show that tuberculosis Molecular 
Bacterial Load Assay (TB- MBLA) reduces time- to- TB- 
bacillary- load- result from days/weeks by culture to hours 
and detects early patient treatment response. By day 14 
of treatment, 5% of patients had cleared bacillary load 
to zero, rising to 58% by 12th week of treatment. Fall 
in bacillary load correlated with mycobacterial growth 
indicator tube culture time- to- positivity (Spearmans 
r=−0.51, 95% CI (−0.56 to −0.46), p<0.0001). Patients 
with high pretreatment bacillary burdens (above the 
cohort bacillary load average of 5.5log10eCFU/ml) 
were less likely to convert- to- negative by 8th week of 
treatment than those with a low burden (below cohort 
bacillary load average), p=0.0005, HR 3.1, 95% CI 
(1.6 to 5.6) irrespective of treatment regimen. TB- 
MBLA distinguished the bactericidal effect of regimens 
revealing the moxifloxacin—20 mg rifampicin regimen 
produced a shorter time to bacillary clearance compared 
with standard- of- care regimen, p=0.008, HR 2.9, 95% CI 
(1.3 to 6.7). Our data show that the TB- MBLA could 
inform clinical decision making in real- time and expedite 
drug TB clinical trials.
InTRoduCTIon
Tuberculosis (TB) is among the top 10 causes of 
death globally and has overtaken HIV/AIDS as 
a leading cause of death from a single infectious 
agent. An estimated 10 million fell ill of TB in 2018 
and approximately 1.5 million died.1 Treatment 
is difficult, requiring a combination of four drugs 
and, depending on whether TB are drug- susceptible 
or drug- resistant, takes as long as 6 or 12 months 
to treat. To help healthcare workers managing TB 
make better decisions, we need to develop effec-
tive methods to monitor the response to treatment. 
Such a marker of treatment response would reduce 
costs associated with prolonged care of patients 
who otherwise already converted to negative, and 
in TB clinical trials by speeding up drug develop-
ment.2 3 Effective methods would help identify 
those who are failing on treatment and require a 
change in therapy or do not convert to negative 
early on in treatment and may require prolonged 
treatment period.4
A high bacterial burden is known to be associated 
with a poor outcome but measuring it is difficult. A 
fall in bacterial burden is the most relevant marker 
of treatment response currently available, but 
culture is technically difficult to standardise and not 
all viable Mycobacterium tuberculosis (Mtb) bacilli 
are detected.5 6 Alternative more rapid methods 
include mycobacterial DNA- detection assays but 
prolonged DNA survival in the host after organisms 
have been killed precludes their use for treatment 
monitoring.7 The tuberculosis Molecular Bacterial 
Load Assay (TB- MBLA), a real- time reverse tran-
scriptase quantitative polymerase chain reaction 
(RT- qPCR), uses more abundant 16S- rRNA as a 
target, increasing its sensitivity to accurately quan-
tify Mtb viable bacillary load to as low as 10 CFU/
mL and over many weeks of treatment.8 9 Treatment 
response (change in bacillary load) can be detected 
as early as 3 days on treatment.8 Here, we report 
the first multicentre evaluation of TB- MBLA in 
comparison to standard- of- care culture methods 
for measuring TB treatment response in three high- 
burden sub- Saharan African countries.
MeThodS
A total of 213 therapy naïve patients with pulmo-
nary TB were enrolled for treatment response 
assessment at four sites in Tanzania (sites 1 and 
2), Mozambique (site 3) and Malawi (site 4). 
The Tanzanian sites were part of the PanACEA 
MAMS- TB clinical trial (NCT01785186) and were 
on different regimens; all other participants were 
on standard of care HRZE (isoniazid, rifampicin, 
pyrazinamide and ethambtul). Serial patient sputum 
samples were collected weekly before and during 
treatment. Treatment responsewas measured over 
12- week treatment period as change bacillary 
(bacterial) load (estimated (e) CFU/mL) meas-
ured by TB- MBLA, compared with culture posi-
tivity and/or culture time- to- positivity (TTP) by 
Lowenstein- Jensen medium and the Mycobacterial 
Growth Indicator Tube (MGIT) culture.
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Figure 1 Bacteriological response to treatment measured by the TB- MBLA (A) and by MGIT (B) at four study sites. The curves indicate the average 
bacillary load reduction mirroring increase in culture time- to- positivity by all patients over a 12- week treatment period. Dots represent individual 
patients at each site. Data points are widely spread in culture, which imply high culture result variability in late stages of treatment. Black curves with 
thick black dots represent clinical trial site 1 and 2 cases. Red curves and red diamond clear symbols represent site 3 cases and blue curves with black 
clear dots represent site 4 cases (MGIT culture stopped at week 8). MGIT, mycobacterial growth indicator tube; TB- MBLA, tuberculosis molecular 
bacterial load assay.
Spearman rank correlation (r) was used to assess relationship 
between change in bacillary load and TTP in response anti- TB 
therapy. Rate of sputum clearance for each patient was calcu-
lated as the SLOPE of the patient bacillary load and TTP over 
time using Microsoft Excel 2016 (y=bacillary load, x=time on 
treatment). Patient ‘conversion’ was defined as a change from 
‘positive’ to ‘negative (two consecutive negative results)’ without 
subsequent reversion to ‘positive’ before the end of 12- week 
follow- up. The day of conversion was defined as the midpoint 
between last positive and first definite negative result. A negative 
result for TB- MBLA was considered at RT- qPCR quantification 
cycle above 30 (zero bacillary load). Patients with above the 
mean cohort bacterial load at baseline were categorised as ‘high 
bacterial load’ and ‘low bacterial load’ for those below the mean. 
HR for conversion to negative by patients with high- baseline 
versus low- baseline bacillary load, HIV+ or HIV- and/or treated 
with experimental regimens compared with standard- of- care 
(control) regimen was examined using Mantel- Cox and Gehan- 
Breslow- Wilcoxon tests. One- way analysis of variance (ANOVA) 
was applied to examine intersite variance in TB- MBLA perfor-
mance. In all analyses, p values were considered significant at 
p<0.05. All statistical tests apart from SLOPE calculations were 
performed in Graphpad Prism V.6.
ReSulTS
Of the 213 patients, 178 (83·6%) patients who completed 
12- week follow- up were included in the analysis. Males, 128 
(71.9%), constituted the majority of cases, 47 (26.4%) were 
HIV- positive and the median age of the whole study group was 
33 years (IQR: 27–40 years). A total of 164 (92%) patients had 
susceptible TB (more details of patient characteristics online 
supplementary figure 1). The rate of bacillary load clearance was 
high,≥1 log10eCFU/ml/week in the first 2 weeks of therapy. As a 
result, 5% (9) patients had converted to zero bacillary load by 
day 14 of treatment. This number rose to 40% (71) and over half 
the cohort, 58.4% (104) by 8th and 12th week of treatment. Fall 
in bacillary load was inversely correlated with increase in TTP 
(Spearman r=−0.51, 95% CI (−0.56 to −0.46), p<0.0001). 
The mean bacillary load at baseline (±SD) was 5.5±1.3 declining 
to 1.7±1.4 at week eight and 0.9±1.2 log10 eCFU/mL at week 
12. MGIT culture TTP, median (range) at baseline was 5 (2−8) 
days, increasing to 21 (16−26) and 25 (14−36) days by week 8 
and 12, respectively (figure 1).
While MGIT time- to- result increased with fall in bacterial 
load, from 5 to 25 days), TB- MBLA time- to- result was the same, 
5±1 hours regardless of the patient bacillary load. Patients with 
high baseline bacterial load were less likely to convert to negative 
by 8th and 12th week of treatment, p=0.0005, HR 3.1, 95% CI 
(1.6 to 5.6) and p=0.0008, HR 2.0, 95% CI (1.3 to 3.1) irrespec-
tive of treatment regimen and rate of sputum bacillary clearance 
in the first 2 weeks of treatment. Among patient characteristics, 
only HIV coinfection reduced the chance to clear bacillary load 
by 12th week of treatment p=0.02, HR 2.1 95% CI (1.2 to 3.7).
TB- MBLA showed that compared with control regimen, the 
rifampicin (RIF) 20 mg/kg plus moxifloxacin and RIF 35 mg/kg 
regimens had significantly higher bactericidal effect, 89% and 
56% conversion to negative by week 12 of treatment (table 1). 
The RIF 35 mg/kg regimen result is consistent with culture in the 
MAMS study,10 even though our study had additional HRZE 
patients from outside the study. TB- MBLA results were repro-
ducible in different laboratory settings, ANOVA p>0.05 and not 
affected by contamination (online supplementary figures 2 and 
3 and table 1)
dISCuSSIon
Confirming the diagnosis and determining whether patient is 
responding to the prescribed therapy is crucial for healthcare 
workers managing patients with TB. In this study, we have 
shown that TB- MBLA gives rapid bacillary load count, which 
responds to therapy in a pattern consistent with liquid culture, 
takes shorter time- to- result and is reproducible in different 
laboratory settings. Early determination of treatment response 
facilitates questions on adherence and/or drug resistance, and 
identifying patients at risk of failing treatment particularly those 
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Table 1 MBLA assessment of the clinical trial regimens compared with standard regimen
Control (RIFhZe) RIF20MhZ RIF35hZe RIF20QhZ Rifqhz
Number analysed 32 18 17 16 16
Number converted by day 56 (week 8) 9 (28%) 11 (61%) 7 (41%) 6 (38%) 3 (19%)
Number converted by day 84 (week 12) 18 (56%) 16 (89%) 10 (59%) 9 (56%) 9 (56%)
Median time to conversion to negative (IQR) 77 (56–84) 56 (42–77) 70 (35–74) 74 (35–84) 70 (56–84)
Log- rank (Mantel- Cox) test
HR (95% CI)   -- 2.9 (1.3–6.7) 2.3 (1.0–5.2) 1.2 (0.5–2.9) 1.1 (0.5–2.5)
P value   -- 0.008 0.049 0.663 0.853
Gehan- Breslow- Wilcoxon test
HR (95% CI)   -- 2.3 (1.4–6.3) 1.9 (1.1–4.9) 1.2 (0.5–2.8) 1.1 (0.5–2.4)
P value   -- 0.008 0.063 0.632 0.791
The RIF20MHZ and RIF35HZE treated cases had significantly shorter conversion time to negative than those treated with standard regimen.
E, Ethambutol; H, Isoniazid; M, Moxifloxacin; Q, SQ09; RIF, Rifampicin; Z, Pyrazinamide.
with high bacillary load. In addition, TB- MBLA simplifies eval-
uation of the impact of comorbidities such as HIV on bacillary 
load clearance during treatment. Compared with the current 
treatment monitoring methods, microscopy is less sensitive and 
cannot distinguish viable from dead bacilli and culture with 
long time- to- result, we believe TB- MBLA has potentially higher 
utility for informing clinical decisions on individual patient 
management and facilitating rapid evaluation of anti- TB drugs 
in clinical trials.
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